Status:
TERMINATED
Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients
Lead Sponsor:
Kaysen, George A., M.D., Ph.D.
Collaborating Sponsors:
Amgen
Dialysis Clinic, Inc.
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Etanercept is a novel anti-inflammatory agent currently used in patients with rheumatoid arthritis. We are examining whether Etanercept is effective in improving the nutritional status of hemodialysis...
Detailed Description
Hemodialysis patients with end stage renal disease have a high mortality rate. In individual patients, mortality is associated with a low serum albumin concentration, a marker of poor nutritional stat...
Eligibility Criteria
Inclusion
- Presence of end stage renal disease
Exclusion
- History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus erythematosis, presence of transcutaneous access (external catheter)
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00293202
Start Date
January 1 2005
End Date
June 1 2010
Last Update
July 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis, Medical Center
Sacramento, California, United States, 95817